ABOUT US

WHO WE ARE

Lentistem Biotech is a R&D company with significant expertise in therapeutic lentiviral vectors and cell engineering forn immunotherapy and gene therapy strategies, with special focus on CAR-T cells therapies.

The company has two proprietary technology platforms for controlling the transgene expression: TCR-like, a synthetic system designed to express the CAR (the transgene) mimicking the physiological behavior of the T-cell receptor interaction, witch improve the fitness of CAR-T cells and prevents overstimulation; and Lent-On-Plus, a fine-tuned exogenously controlled and first-in-class synthetic gene expression system favored for clinics, which among other applications, can be implemented for safer and efficient next generation of CAR-T cells against hematological and solid tumors.

OUR PURPOSE

Our MISSION is to develop new technologies to improve the efficacy and safety of cancer immunotherapy (CAR-T cells). LentiStem endeavors to develop best-in-class therapeutical vectors for precision gene therapy, for safer and more efficient therapies to cure hard-to-treat diseases such as refractory cancers.

OUR HISTORY

LentiStem is founded in 2016 on the patented technologies for the contol of expression in engineered cells developed by Prof. Francisco Martin and his team, and spun-out from the Fundación Progreso y Salud. Since 2019, the company has been growing, stablishing the state-of-art of the platforms and advancing in the development of therapeutical product candidates. We have facilities for molecular analysis, cell biology, small animal research and cell-culture facilities with P2-level safety standards to produce the highest grade viral vectors. Besides, our team is working in collaboration with several hospitals, academic labs and government agencies in Spain to create cost-effective and precise advanced gene-based therapies.

The company has exclusive license to multiple technologies, which are currently being used in 18 labs worldwide and cited in more than 70 peer-reviewed scientific publications.